Latest News

In February 2014: Godwyn Francis, Business Development – Head, Aagami, will be attending Bio India (Feb 10-12, 2014) at Bangalore and Bio Asia 2014 (February 17-19, 2014) at Hyderabad, India. The key objective of attending these events is to showcase Aagami's global clients' licensing, co-development partnering opportunities.

Aagami regularly participates in Global events in Lifesciences, which are very productive platforms to facilitate partnerships. Most recently, Aagami CEO Mr Dinesh Jain participated in Biotech showcase as well as JP Morgan, meeting more than 50 companies. Many of these meetings proved to be very fruitful.


January 27, 2014: An Oregon drug Development Company with innovative technology licensed from Portland State University, is developing two antimalarial drugs and one antibacterial. Today they have requested Aagami again to support their partnering needs with Indian Pharmaceutical companies.

In the last assignment ( in 2012), Aagami took them to 6 qualified and interested companies. As an outcome of those meetings, it was decided that the company would need further development on their programs before partnering/out-licensing. The Oregon company is now ready with their programs to go to the clinic within this year, and based on their trust and previous experience, requested Aagami to team up for partnering with Indian companies again, including the newer companies.


Jan 07, 2013: Aagami has been chosen by an Indian company, a first win. It has been appointed by an Indian company for Out Licensing their innovatively developed anti-infective asset for the US market. Aagami looks forward to supporting its first ever Indian client to find an appropriate product company in the US market. The company has launched this asset successfully in India in Jan 2013 and partnered it for Latin America and South Africa. The asset is also about to receive market authorisation in Europe.


In January 2014, Dinesh Jain, CEO of Aagami a will attend J P Morgan Healthcare conference and Biotech Showcase conference respectively. Like many other thousands of executives of Life Sciences and Healthcare companies across the world, the 2 events remain an annual pilgrimage for Aagami too.

We look forward to meeting like minded professionals for exploring partnering, investments, opportunities together to further cause of the industry. Aagami acts as the much needed bridge between Global companies and emerging markets like India and Asia.

Riding high on bringing multiple successes to a client recently, Aagami looks forward to find new challenges and also represent a dozen of its esteemed clients.

Bangalore, India and Freising, Germany, December 17, 2013 

Pieris AG, a next generation therapeutic protein R&D Company, and Stelis Biopharma, a subsidiary of Bangalore-based Strides Arcolab Ltd, had entered into a long-term agreement for worldwide development and commercialisation of a protein molecule- Anticalin®, primarily focused on ophthalmology.

As per the agreement, Pieris will take care of early stages of development in each collaborative programme using a novel Anticalin-based protein, while Stelis will be responsible for advancing the molecule through a first-in-human clinical study and drug manufacturing, the company said in a statement.

The collaboration will see the merger of Pieris' innovative drug discovery and early development capabilities with Stelis' strong bio-manufacturing and clinical development expertise.